Hudson Bay Capital Management
PPBT

Hudson Bay Capital Management’s Purple Biotech PPBT Stock Holding History

Hudson Bay Capital Management’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-238
Closed -$145K – 549
2020
Q1 		$145K Buy
+238
New +$292K ﹤0.01% 409

Other funds holding PPBT

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
BFC
Bedel Financial Consulting Indianapolis, Indiana $1.06B AUM 38.33% 1-Year Est. Return

Hudson Bay Capital Management's PPBT Position: Q2 2020 in Review

Hudson Bay Capital Management sold out of Purple Biotech (PPBT) in Q2 2020, closing a stake of 238 shares — an estimated $145K sold.

Hudson Bay Capital Management first reported a position in PPBT in Q1 2020 and held it in 1 quarter. The position peaked at $145K in Q1 2020. 29 funds tracked by Wall St. Rank hold PPBT as of Q2 2020.

  • Hudson Bay Capital Management reported no remaining Purple Biotech position as of Q2 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 238 Purple Biotech shares in Q2 2020, an estimated $145K.
  • Hudson Bay Capital Management first reported a position in Purple Biotech in Q1 2020 and held it in 1 quarter.
  • Hudson Bay Capital Management's Purple Biotech position peaked at $145K in Q1 2020.
  • 29 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2020.

Based on Hudson Bay Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.